How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azelastine-fluticasone-nasal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Azelastine-Fluticasone Nasal — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azelastine-Fluticasone Nasal (Azelastine-Fluticasone Nasal) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihistamine/Intranasal corticosteroid combination. Area: Allergy/Immunology.

marketed Antihistamine/Intranasal corticosteroid combination H1 receptor (azelastine); Glucocorticoid receptor (fluticasone) Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Azelastine-Fluticasone Nasal (Azelastine-Fluticasone Nasal) — University of Dundee. Azelastine blocks histamine receptors to reduce allergic inflammation, while fluticasone suppresses immune response via glucocorticoid receptor activation in the nasal cavity.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azelastine-Fluticasone Nasal TARGET	Azelastine-Fluticasone Nasal	University of Dundee	marketed	Antihistamine/Intranasal corticosteroid combination	H1 receptor (azelastine); Glucocorticoid receptor (fluticasone)
DYMISTA nasal spray	DYMISTA nasal spray	Glenmark Pharmaceuticals Ltd. India	phase 3	Antihistamine/Intranasal corticosteroid combination	H1 receptor (azelastine); Glucocorticoid receptor (fluticasone propionate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihistamine/Intranasal corticosteroid combination class)

Glenmark Pharmaceuticals Ltd. India · 1 drug in this class
University of Dundee · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azelastine-Fluticasone Nasal — Competitive Intelligence Brief. https://druglandscape.com/ci/azelastine-fluticasone-nasal. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab